Assays In-Depth Focus 2017
Posted: 15 March 2017 | Anton Simeonov, Del Trezise, Horst Flotow, Madhu Lal-Nag | No comments yet
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton Simeonov, National Institutes of Health (NIH), explain how 3-D models can be used in HTS, and lead to a significant decrease in the attrition of drug failure rates in clinical trials…
Included in this Assays In-Depth Focus:
- Whole animal screening: back to the future
Horst Flotow, Hit Discovery Contance (HDC) GmbH - Application Note: Thermo Scientific
- High-throughput screening platforms incorporating physiologically relevant 3-D models
Madhu Lal-Nag, National Center for Advancing Translational Sciences (NCATS) and Anton Simeonov, National Institutes of Health (NIH)
This Assays In-Depth Focus is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Assays, Cell-based assays, Drug Development, Drug Discovery, Drug Targets, High Throughput Screening (HTS), Immunoassays, Screening
Related organisations
Essen BioScience, Hit Discovery Constance, National Center for Advancing Translational Sciences, National Institutes of Health (NIH), Thermo Fisher Scientific
Related people
Anton Simeonov, Del Trezise, Horst Flotow, Madhu Lal-Nag